Skip to main content

Avalyn Pharma Inc 8-K, filed Nov 12, 2026

Avalyn Pharma Inc. (AVLN)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 8-K

Avalyn Pharma Inc filed this 8-K on November 12, 2026.

Avalyn Pharma Inc. started a Phase 1 study of AP03 in healthy volunteers. It had $386.6 million in cash, cash equivalents and marketable securities on September 30, 2026, with runway projected into 2029; third-quarter net loss was $29.7 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits